| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FBXL6 |
| Uniprot No | Q8N531 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-539aa |
| 氨基酸序列 | MAAPASRQVRRRARAAPRPRSAEDWWWDRLAPRGSGYHLLQSDSMLLVLSEPGPARPRAQRRASRRTPRQPPRGPSAAAKPKAGLRSEAAAAPAPAPAPTPTPEEGPDAGWGDRIPLEILVQIFGLLVAADGPMPFLGRAARVCRRWQEAASQPALWHTVTLSSPLVGRPAKGGVKAEKKLLASLEWLMPNRFSQLQRLTLIHWKSQVHPVLKLVGECCPRLTFLKLSGCHGVTADALVMLAKACCQLHSLDLQHSMVESTAVVSFLEEAGSRMRKLWLTYSSQTTAILGALLGSCCPQLQVLEVSTGINRNSIPLQLPVEALQKGCPQLQVLRLLNLMWLPKPPGRGVAPGPGFPSLEELCLASSTCNFVSNEVLGRLLHGSPNLRLLDLRGCARITPAGLQDLPCRELEQLHLGLYGTSDRLTLAKEGSPFLTQKWCHTLRELDLSGQGFSEKDLEQALAAFLSTPGGSHPALCSLNLRGTRVTPSTVSSVISSCPGLLYLNLESCRCLPRGLKRAYRGLEEVQWCLEQLLTSPSPS |
| 分子量 | 85 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人FBXL6蛋白的3篇参考文献的概括(文献为假设性示例，实际引用时请核实原文)：
1. **《Structural Basis of FBXL6-Mediated Ubiquitination》**
**作者：Zhang Y. et al. (2021)**
**摘要**：本研究解析了重组人FBXL6蛋白的晶体结构，揭示了其F-box结构域与SKP1的结合模式，以及C端富含亮氨酸重复序列(LRR)对底物特异性识别的关键作用，为靶向FBXL6的药物开发提供了结构依据。
2. **《FBXL6 Promotes Tumor Metastasis via Degradation of TIMP3 in Colorectal Cancer》**
**作者：Xu L. et al. (2020)**
**摘要**：通过表达重组人FBXL6蛋白，研究发现其作为E3泛素连接酶复合体组分，特异性识别并泛素化降解金属蛋白酶抑制因子TIMP3.从而增强结直肠癌细胞侵袭能力，提示FBXL6可能成为癌症治疗的潜在靶点。
3. **《FBXL6 Regulates Mitochondrial Autophagy through PINK1/Parkin Pathway》**
**作者：Lin H. et al. (2022)**
**摘要**：利用重组FBXL6蛋白进行功能实验，发现其通过调控PINK1稳定性影响线粒体自噬过程，在帕金森病模型中干预FBXL6可缓解神经元损伤，揭示了FBXL6在神经退行性疾病中的新机制。
**注意**：以上为模拟摘要，实际文献需查询PubMed/Google Scholar等平台，以关键词“recombinant human FBXL6”“FBXL6 ubiquitination”等进行检索。
FBXL6 (F-box and leucine-rich repeat protein 6) is a member of the F-box protein family, which functions as a substrate recognition component of the SCF (SKP1-Cullin-F-box) E3 ubiquitin ligase complex. This complex plays a pivotal role in the ubiquitin-proteasome system, tagging specific target proteins with ubiquitin for proteasomal degradation. Structurally, FBXL6 contains an N-terminal F-box domain that interacts with SKP1 to anchor the protein to the SCF complex and a C-terminal leucine-rich repeat (LRR) domain implicated in substrate binding.
Recombinant human FBXL6 protein is engineered through genetic modification, typically expressed in mammalian or bacterial systems, to enable functional studies. Its production allows researchers to explore substrate interactions, post-translational modifications, and regulatory mechanisms in cellular processes such as cell cycle progression, apoptosis, and stress response. Dysregulation of FBXL6 has been linked to diseases, including cancers and metabolic disorders, highlighting its potential as a therapeutic target.
Studies using recombinant FBXL6 have provided insights into its role in degrading substrates like pyruvate kinase M2 (PKM2), influencing cellular metabolism. Its recombinant form is essential for biochemical assays, crystallography, and drug screening to identify modulators of its activity. Understanding FBXL6's molecular interactions aids in deciphering its physiological and pathological significance, advancing both basic research and translational applications in precision medicine.
×
